208 related articles for article (PubMed ID: 29272692)
1. Recent endeavors in MECP2 gene transfer for gene therapy of Rett syndrome.
Sinnett SE; Gray SJ
Discov Med; 2017 Oct; 24(132):153-159. PubMed ID: 29272692
[TBL] [Abstract][Full Text] [Related]
2. Severe offtarget effects following intravenous delivery of AAV9-MECP2 in a female mouse model of Rett syndrome.
Matagne V; Borloz E; Ehinger Y; Saidi L; Villard L; Roux JC
Neurobiol Dis; 2021 Feb; 149():105235. PubMed ID: 33383186
[TBL] [Abstract][Full Text] [Related]
3. A codon-optimized Mecp2 transgene corrects breathing deficits and improves survival in a mouse model of Rett syndrome.
Matagne V; Ehinger Y; Saidi L; Borges-Correia A; Barkats M; Bartoli M; Villard L; Roux JC
Neurobiol Dis; 2017 Mar; 99():1-11. PubMed ID: 27974239
[TBL] [Abstract][Full Text] [Related]
4. Engineered microRNA-based regulatory element permits safe high-dose miniMECP2 gene therapy in Rett mice.
Sinnett SE; Boyle E; Lyons C; Gray SJ
Brain; 2021 Nov; 144(10):3005-3019. PubMed ID: 33950254
[TBL] [Abstract][Full Text] [Related]
5. MECP2 isoform-specific vectors with regulated expression for Rett syndrome gene therapy.
Rastegar M; Hotta A; Pasceri P; Makarem M; Cheung AY; Elliott S; Park KJ; Adachi M; Jones FS; Clarke ID; Dirks P; Ellis J
PLoS One; 2009 Aug; 4(8):e6810. PubMed ID: 19710912
[TBL] [Abstract][Full Text] [Related]
6. MeCP2 and Rett syndrome: reversibility and potential avenues for therapy.
Gadalla KK; Bailey ME; Cobb SR
Biochem J; 2011 Oct; 439(1):1-14. PubMed ID: 21916843
[TBL] [Abstract][Full Text] [Related]
7. Exploring the possible link between MeCP2 and oxidative stress in Rett syndrome.
Filosa S; Pecorelli A; D'Esposito M; Valacchi G; Hajek J
Free Radic Biol Med; 2015 Nov; 88(Pt A):81-90. PubMed ID: 25960047
[TBL] [Abstract][Full Text] [Related]
8. Profiling beneficial and potential adverse effects of MeCP2 overexpression in a hypomorphic Rett syndrome mouse model.
Vermudez SAD; Gogliotti RG; Arthur B; Buch A; Morales C; Moxley Y; Rajpal H; Conn PJ; Niswender CM
Genes Brain Behav; 2022 Jan; 21(1):e12752. PubMed ID: 34002468
[TBL] [Abstract][Full Text] [Related]
9. Improved survival and reduced phenotypic severity following AAV9/MECP2 gene transfer to neonatal and juvenile male Mecp2 knockout mice.
Gadalla KK; Bailey ME; Spike RC; Ross PD; Woodard KT; Kalburgi SN; Bachaboina L; Deng JV; West AE; Samulski RJ; Gray SJ; Cobb SR
Mol Ther; 2013 Jan; 21(1):18-30. PubMed ID: 23011033
[TBL] [Abstract][Full Text] [Related]
10. The Efficacy of a Human-Ready mini
Sadhu C; Lyons C; Oh J; Jagadeeswaran I; Gray SJ; Sinnett SE
Genes (Basel); 2023 Dec; 15(1):. PubMed ID: 38254921
[TBL] [Abstract][Full Text] [Related]
11. Regulation mechanism and research progress of MeCP2 in Rett syndrome.
Yang W; Pan H
Yi Chuan; 2014 Jul; 36(7):625-30. PubMed ID: 25076025
[TBL] [Abstract][Full Text] [Related]
12. The molecular pathology of Rett syndrome: synopsis and update.
Akbarian S; Jiang Y; Laforet G
Neuromolecular Med; 2006; 8(4):485-94. PubMed ID: 17028371
[TBL] [Abstract][Full Text] [Related]
13. MeCP2 binds to non-CG methylated DNA as neurons mature, influencing transcription and the timing of onset for Rett syndrome.
Chen L; Chen K; Lavery LA; Baker SA; Shaw CA; Li W; Zoghbi HY
Proc Natl Acad Sci U S A; 2015 Apr; 112(17):5509-14. PubMed ID: 25870282
[TBL] [Abstract][Full Text] [Related]
14. Transcriptomic Studies in Mouse Models of Rett Syndrome: A Review.
Sanfeliu A; Kaufmann WE; Gill M; Guasoni P; Tropea D
Neuroscience; 2019 Aug; 413():183-205. PubMed ID: 31229631
[TBL] [Abstract][Full Text] [Related]
15. Deciphering Rett syndrome with mouse genetics, epigenomics, and human neurons.
Tao J; Wu H; Sun YE
Int Rev Neurobiol; 2009; 89():147-60. PubMed ID: 19900619
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of genetic MECP2 supplementation in the R294X mouse model of Rett syndrome.
Collins BE; Merritt JK; Erickson KR; Neul JL
Genes Brain Behav; 2022 Jan; 21(1):e12739. PubMed ID: 33942492
[TBL] [Abstract][Full Text] [Related]
17. FXYD1 is an MeCP2 target gene overexpressed in the brains of Rett syndrome patients and Mecp2-null mice.
Deng V; Matagne V; Banine F; Frerking M; Ohliger P; Budden S; Pevsner J; Dissen GA; Sherman LS; Ojeda SR
Hum Mol Genet; 2007 Mar; 16(6):640-50. PubMed ID: 17309881
[TBL] [Abstract][Full Text] [Related]
18. Novel MECP2 gene therapy is effective in a multicenter study using two mouse models of Rett syndrome and is safe in non-human primates.
Powers S; Likhite S; Gadalla KK; Miranda CJ; Huffenberger AJ; Dennys C; Foust KD; Morales P; Pierson CR; Rinaldi F; Perry S; Bolon B; Wein N; Cobb S; Kaspar BK; Meyer KC
Mol Ther; 2023 Sep; 31(9):2767-2782. PubMed ID: 37481701
[TBL] [Abstract][Full Text] [Related]
19. Rett syndrome and the urge of novel approaches to study MeCP2 functions and mechanisms of action.
Bedogni F; Rossi RL; Galli F; Cobolli Gigli C; Gandaglia A; Kilstrup-Nielsen C; Landsberger N
Neurosci Biobehav Rev; 2014 Oct; 46 Pt 2():187-201. PubMed ID: 24594195
[TBL] [Abstract][Full Text] [Related]
20. MECP2 mutations and clinical correlations in Greek children with Rett syndrome and associated neurodevelopmental disorders.
Psoni S; Sofocleous C; Traeger-Synodinos J; Kitsiou-Tzeli S; Kanavakis E; Fryssira-Kanioura H
Brain Dev; 2012 Jun; 34(6):487-95. PubMed ID: 21982064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
